With 1.01 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $26.5727 whereas the lowest price it dropped to was $19.12. The 52-week range on ZBIO shows that it touched its highest point at $26.25 and its lowest point at $5.83 during that stretch. It currently has a 1-year price target of $33.57. Beta for the stock currently stands at -1.60.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZBIO was up-trending over the past week, with a rise of 17.09%, but this was up by 18.59% over a month. Three-month performance surged to 114.58% while six-month performance rose 282.57%. The stock gained 216.24% in the past year, while it has gained 37.69% so far this year. A look at the trailing 12-month EPS for ZBIO yields -4.23 with Next year EPS estimates of -4.33. For the next quarter, that number is -0.67. This implies an EPS growth rate of 71.19% for this year and -26.53% for next year.
Float and Shares Shorts:
At present, 42.09 million ZBIO shares are outstanding with a float of 10.31 million shares on hand for trading. On 2025-09-15, short shares totaled 5.55 million, which was 1318.0 higher than short shares on 1755216000. In addition to Mr. Leon Oliver Moulder Jr., M.B.A. as the firm’s CEO & Chairman of the Board, Mr. Joseph L. Farmer serves as its COO & President.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, ZBIO reported revenue of $0.0 and operating income of -$55163000.0. The EBITDA in the recently reported quarter was -$55151000.0 and diluted EPS was -$1.25.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ZBIO analysts setting a high price target of 45.0 and a low target of 24.0, the average target price over the next 12 months is 33.57143. Based on these targets, ZBIO could surge 73.75% to reach the target high and fall by -7.34% to reach the target low. Reaching the average price target will result in a growth of 29.62% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$4.36561 being high and -$9.18614 being low. For ZBIO, this leads to a yearly average estimate of -$6.5125. The surprise factor in the prior quarter was -$1.03. Based on analyst estimates, the high estimate for the next quarter is $1.55 and the low estimate is -$1.2. The average estimate for the next quarter is thus $0.17.
